The outcome and safety of re-challenge Lutetium-177 PSMA (177Lu-PSMA) therapy with Low-Dose Docetaxel as a Radiosensitizer—a promising combination in metastatic castrate-resistant prostate cancer (mCRPC) : a case report
Loading...
Date
Authors
Maharaj, Masha
Heslop, Lucille
Govender, Trisha
Korowlay, Nisaar
Singh, Aviral
Choudhary, Partha
Sathekge, Mike Machaba
Journal Title
Journal ISSN
Volume Title
Publisher
Springer
Abstract
Please read abstract in the article.
Description
Keywords
Prostate-specific membrane antigen (PSMA), Lutetium-177 (177Lu), Docetaxel, Prostate cancer, Radiosensitizer, Re-challenge, Radioligand therapy (RLT), Metastatic castrate-resistant prostate cancer (mCRPC)
Sustainable Development Goals
Citation
Maharaj, M., Heslop, L., Govender, T. et al. The Outcome and Safety of Re-challenge Lutetium-177 PSMA (177Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer—a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report. Nuclear Medicine and Molecular Imaging 55, 136–140 (2021). https://doi.org/10.1007/s13139-021-00696-5.